LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.57 Average PT from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $94.57.

A number of brokerages have issued reports on LMAT. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target for the company. Oppenheimer restated an "outperform" rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Finally, Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a report on Friday, November 1st.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded down $0.74 during trading hours on Monday, reaching $91.38. 131,356 shares of the stock were exchanged, compared to its average volume of 131,708. The business's fifty day moving average is $97.74 and its two-hundred day moving average is $90.16. The firm has a market capitalization of $2.05 billion, a P/E ratio of 49.93, a P/E/G ratio of 2.47 and a beta of 0.93. LeMaitre Vascular has a 12-month low of $52.88 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company's quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.33 EPS. As a group, equities research analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular's payout ratio is currently 34.97%.

Insider Activity

In related news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 10.79% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Conestoga Capital Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 1.9% in the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier's stock valued at $183,769,000 after acquiring an additional 36,850 shares in the last quarter. Copeland Capital Management LLC lifted its position in LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock valued at $108,068,000 after purchasing an additional 11,318 shares during the period. State Street Corp boosted its holdings in LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock valued at $76,363,000 after purchasing an additional 28,525 shares in the last quarter. Congress Asset Management Co. increased its position in LeMaitre Vascular by 2.6% during the 3rd quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier's stock worth $65,888,000 after purchasing an additional 18,295 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of LeMaitre Vascular by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier's stock worth $50,403,000 after buying an additional 23,443 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.